Drug Trial Radar · NCT06295731
Ordastobart (INBRX-106) Add-on to Pembrolizumab in 1L HPV+ PD-L1+ R/M OPSCC (HexAgon-HN)
Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
450
Planned (sponsor's estimate)
Start
May 14, 2024
Primary completion
Dec 2029
Study completion May 2031
Sponsor
- Lead sponsor
- Inhibrx Biosciences, IncIndustry
- Sponsor type
- Industry
- First posted
- Mar 6, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This seamless phase 2/3 randomized controlled study will evaluate the efficacy and safety of the hexavalent OX40 agonist antibody ordastobart (INBRX-106) combined with the anti-PD-1 antibody pembrolizumab versus pembrolizumab (+ placebo in phase 3) as first-line treatment for patients with recurrent or metastatic (R/M) HPV-positive Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC) expressing PD-L1.
Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC)
- HPV Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC)
Interventions
INBRX-106Drug
INBRX-106 0.1 mg/kg by intravenous (IV) infusion, given every 3 weeks (QW3)
PembrolizumabDrug
Pembrolizumab 200 mg by intravenous (IV) infusion, given every 3 weeks (QW3)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 2: Objective Response Rate by investigator (ORRinv)Time frame: From randomization to progressive disease (PD) or death (up to 1 year)
- Phase 3: Progression-Free Survival by Investigator (PFSinv)Time frame: From randomization to PD or death (up to 4 years)
- Phase 3: Overall Survival (OS)Time frame: From randomization until death from any cause (up to 4 years)
Locations
89 sites in 13 countries. Site status is shown where the registry gives one.
City of Hope Medical Center
Duarte, California · Recruiting
Los Angeles Cancer Network (LACN)
Los Angeles, California · Recruiting
Sutter Health
Sacramento, California · Withdrawn
UC Davis
Sacramento, California · Terminated
Medical Oncology Associates of San Diego
San Diego, California · Recruiting
Sarcoma Oncology Center
Santa Monica, California · Recruiting
ChristianaCare Health Services
Newark, Delaware · Active not recruiting
University of Florida UF Health Cancer Center
Gainesville, Florida · Active not recruiting
The Oncology Institute of Hope & Innovation
Miami, Florida · Recruiting
Mid Florida Hematology and Oncology Center
Orange City, Florida · Recruiting
Cleveland Clinic Florida, The Maroone Cancer Center
Weston, Florida · Active not recruiting
University of Illinois Cancer Center
Chicago, Illinois · Recruiting
Norton Cancer Institute
Louisville, Kentucky · Recruiting
Massachusetts General Hospital
Boston, Massachusetts · Active not recruiting
Karmanos Cancer Institute
Detroit, Michigan · Recruiting
Washington University St. Louis
St Louis, Missouri · Recruiting
Intermountain Health, St. Vincent Regional Hospital, Cancer Centers of Montana
Billings, Montana · Recruiting
Oncology Hematology West, PC dba Nebraska Cancer Specialists
Omaha, Nebraska · Recruiting
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada · Recruiting
Christus St. Vincent Regional Cancer Center
Santa Fe, New Mexico · Recruiting
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina · Recruiting
Oklahoma University Stephenson Cancer Center
Oklahoma City, Oklahoma · Recruiting
Oregon Health & Science University
Portland, Oregon · Active not recruiting
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania · Recruiting
CHRISTUS Spohn Cancer Center
Corpus Christi, Texas · Recruiting
VCU Massey Comprehensive Cancer Center
Richmond, Virginia · Recruiting
Royal Adelaide Hospital
Adelaide, South Australia, Australia · Active not recruiting
University Hospital Brussels
Jette, Belgium · Active not recruiting
Chu Ucl Namur Site De Sainte-Elisabeth
Namur, Belgium · Active not recruiting
Vitaz
Sint-Niklaas, Belgium · Active not recruiting
Antwerp University Hospital
Edegem, Antwerp, Belgium · Active not recruiting
Multiprofile Hospital for Active Treatment - "Uni Hospital" Ltd, Medical Oncology Dept
Panagyurishte, Bulgaria · Active not recruiting
Complex Oncological Center Plovdiv EOOD Dept of Med Oncology and Oncological Diseases in Hematology
Plovdiv, Bulgaria · Active not recruiting
Uni Multiprofile Hospital for Active Treatment Tsaritsa Yoanna - ISUL EAD Clinic of Medical Oncology
Sofia, Bulgaria · Active not recruiting
Multiprofile Hospital for Active Treatment Sveta Sofia, Department of Medical Oncology
Sofia, Bulgaria · Active not recruiting
Centre Jean Perrin
Clermont-Ferrand, France · Active not recruiting
Cenre Oscar Lambret
Lille, France · Active not recruiting
Centre Leon Berard
Lyon, France · Active not recruiting
CH Annecy Genevois
Annecy, Epagny Metz Tessy, France · Active not recruiting
UNEOS-Hopital R.SCHUMAN
Metz, Moselle, France · Active not recruiting
Showing 40 of 89 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.